Target intelligence / Profile preview

Eukaryotic translation elongation factor 1 gamma pseudogene 8 (EEF1GP8)

Target: EEF1GP8
Molecular classification: Other (classified specifically as a processed pseudogene of EEF1G)

Overview

Eukaryotic translation elongation factor 1 gamma pseudogene 8 (EEF1GP8) is a human processed pseudogene predicted based on genome sequence analysis. It is related to the parental gene EEF1G, which encodes a protein involved in the elongation phase of translation. To date, EEF1GP8 has no supporting experimental evidence for transcription, functional protein product, or biological activity. It is not considered a therapeutic target, biomarker, or functional gene, and has no documented implications in disease or drug interactions. Its designation is bioinformatically predicted and not functionally supported[1].

Other names: EEF1GP8

Beyond the preview

Go deeper on Eukaryotic translation elongation factor 1 gamma pseudogene 8 (EEF1GP8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eukaryotic translation elongation factor 1 gamma pseudogene 8 (EEF1GP8).

Explore the full profile